0.25
-0.0104(-4.00%)
Currency In USD
| Previous Close | 0.26 |
| Open | 0.25 |
| Day High | 0.26 |
| Day Low | 0.24 |
| 52-Week High | 1.56 |
| 52-Week Low | 0.23 |
| Volume | 559,675 |
| Average Volume | 2.43M |
| Market Cap | 22.31M |
| PE | -0.12 |
| EPS | -2.03 |
| Moving Average 50 Days | 0.55 |
| Moving Average 200 Days | 0.84 |
| Change | -0.01 |
If you invested $1000 in Allakos Inc. (ALLK) since IPO date, it would be worth $7.99 as of March 13, 2025 at a share price of $0.25. Whereas If you bought $1000 worth of Allakos Inc. (ALLK) shares 5 years ago, it would be worth $4.75 as of March 13, 2025 at a share price of $0.25.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Allakos Announces Topline Results from its Phase 1 Trial of AK006 in Patients with Chronic Spontaneous Urticaria and Announces Restructuring
GlobeNewswire Inc.
Jan 27, 2025 12:00 PM GMT
– AK006 did not demonstrate therapeutic activity in CSU –– Allakos will discontinue further development of AK006, reduce workforce by 75% and explore strategic alternatives –– Management to host conference call and webcast today at 8:30 am E.T. – SAN
Allakos Provides Business Update and Reports Third Quarter 2024 Financial Results
GlobeNewswire Inc.
Nov 06, 2024 9:02 PM GMT
SAN CARLOS, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business updat
Allakos Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy Volunteers
GlobeNewswire Inc.
Oct 10, 2024 8:02 PM GMT
– Subcutaneously administered AK006 showed approximately 77% bioavailability and prolonged receptor occupancy on mast cells –– Subcutaneous AK006 was well-tolerated with a favorable safety profile –– Top-line Phase 1 results of Intravenous AK006 in p